Skip to main content
Premium Trial:

Request an Annual Quote

Helene Peyro-Saint-Paul, Pascale Beurdeley, and Jean-Marie Charpin

PathoQuest has announced an expansion of its executive team by appointing Helene Peyro-Saint-Paul as chief medical officer, Pascale Beurdeley as CSO, and Jean-Marie Charpin as global commercial head of viral safety.

In her role as CMO, Peyro-Saint-Paul will be in charge of medical affairs, development strategy, and market access. Most recently, Peyro-Saint-Paul served as CMO at Qiagen Marseille, formerly Ipsogen, and HalioDx, a company she co-founded. In her role as CSO, Beurdeley will lead PathoQuest's research and development activities while providing insight and expertise on all the scientific aspects of the company's technology. Most recently Beurdeley held several positions at DiaxonHit, formerly ExonHit Therapeutics, where she contributed to the development and promotion of the company's proprietary platform for the analysis of gene expression and alternative splicing. In his role as commercial head of viral safety, Charpin will drive commercial efforts associated with PathoQuest's viral safety testing business. Most recently, he served as business account manager and product manager at OncoDesign, where he developed the business in north Europe and successfully launched innovative services for preclinical oncology worldwide.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more